Skip to main content
EPSCoR/IDeA Coalition
BIOMEDICAL RESEARCH

FDA Approves Merck Oral Combination for HIV Treatment

The U.S. Food and Drug Administration approved a new once-daily oral combination therapy from Merck for certain adults with HIV, offering an additional option for managing the condition.

The U.S. Food and Drug Administration approved a new once-daily oral combination therapy from Merck for certain adults with HIV. The treatment offers an additional option for managing the condition and may replace existing regimens for some patients.

National coordination, local impact.

EPSCoR and IDeA programs operate in 25 states and 3 territories. Each state has a dedicated program office coordinating research investments, workforce development, and federal partnerships.